Criteria | Structured Finance | CDOs: Global Cash Flow And Synthetic CDO Criteria: CDOs Of Structured Finance Securities Mar 02

  • ID: 1833867
  • March 2002
  • Region: Global
  • Standard & Poors
1 of 2

Editor's Note: This article has been partially superseded by the articles titled: "Advance Notice Of Proposed Criteria Change: Market Conditions Negatively Impact CDOs Of Structured Finance Securities," published Dec. 30, 2008; "Retranching CDOs Of ABS With Substantial Exposure To Certain U.S. RMBS And CDO Securities," Dec. 18, 2008; "Recovery Assumptions Revised For U.S. RMBS Collateral Backing ABS CDO Transactions," Oct. 17, 2008; "Recovery Assumptions Revised For Certain CDOs Backed Predominantly By U.S. RMBS," April 28, 2008; "The Use Of Rating-Based Haircuts In Event Of Default Overcollateralization Tests For CDOs," March 19, 2008; "S&P Comments On Process For Rating New CDOs With U.S. RMBS Exposure," July 18, 2007;" and "Update To General Cash Flow Analytics Criteria For CDO Securitizations," published Oct....

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Commentary
Criteria articles describe the thought process and methodology Standard & Poor's analysts use in determining ratings. These commentary pieces discuss both the quantitative (economic and financial) and qualitative (business analysis and caliber of management) aspects of the analysis, as well as legal issues.

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.